Merck's PD-1 inhibitor pembrolizumab injection approved in China

According to Merck China news, on September 29, Merck announced that the subcutaneous injection formulation of its PD-1 inhibitor pembrolizumab injection has been approved by China's National Medical Products Administration, covering 19 solid tumor indications, making it the first and currently only PD-1 inhibitor approved with a subcutaneous injection formulation in China.